Audentes Therapeutics

Audentes Therapeutics
Last activity: 28.06.2020
Categories: LifeInvestmentHealthTechFirmDevelopmentBioTechAppManagementPublicTechnology
Developing TherapiesTo Transform Lives Astellas Gene Therapies is an Astellas Center of Excellence developing genetic medicines with the potential to deliver transformative value for patients. Innovative Therapies Our investigational therapies target rare diseases through three modalities: gene replacement, exon skipping gene therapy and vectorized RNA knockdown.
Employees: 201-500
Total raised: $337.5M
Founded date: 2012

Investors 7

Funding Rounds 4

13.10.2015Series C$65M-
02.12.2014Series B$42.5M-
18.07.2013Series A$30M-

Mentions in press and media 15

28.06.2020Two patients die in Audentes gene therapy study, heightening...Two patients in a study of a high-dose gene therapy for a rare muscle disorder have died, heightenin...statnews.c...
26.08.2016Sofinnova Ventures has raised $595M for its largest fund to ...The company’s strategy of investing in late-stage private companies has found some receptive buyers ...medcitynew...
04.01.2016Biotech Startups Hit the Ground Running, With Six Filing IPO...If we had to gamble on it, we’d bet the IPO market will be far more brisk this year than last year, ...techcrunch...
13.10.2015Audentes Therapeutics Closes $65M Series C FinancingAudentes Therapeutics, Inc., a San Francisco, CA-based biotechnology company committed to the
13.10.2015Daily funding roundup - October 13, 2015EverString raised $65M; Audentes Therapeutics bagged $65M; SteelBrick received $48M Predictive
13.10.2015Gene therapy player Audentes Therapeutics raises $65MThe round was led by existing investor Sofinnova Ventures and new investor Redmiel Group. Other part...medcitynew...
04.12.2014West Coast Biotech Roundup: Amgen, Ariosa, Avanir, Audentes ...Share Share on Facebook Share on Twitter LinkedIn Email Reprints Where is biotech innovation? All
02.12.2014Audentes Therapeutics Closes $42.5M Series B FinancingAudentes Therapeutics, Inc., a San Francisco, CA-based biotechnology company committed to the
18.10.2013Health IT deals help push software deals to 12-year high but...Here were the biggest health IT deals for the quarter based on data from the MoneyTree Report and Me...medcitynew...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In